Novo Nordisk Valuation
Is NNO2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NNO2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NNO2 (€94.6) is trading below our estimate of fair value (€151.74)
Significantly Below Fair Value: NNO2 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NNO2?
Key metric: As NNO2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is NNO2's PE Ratio? | |
|---|---|
| PE Ratio | 33.3x |
| Earnings | DKK 94.72b |
| Market Cap | DKK 3.15t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.6x |
| Enterprise Value/EBITDA | 24.6x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does NNO2's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 38.8x | ||
LLY Eli Lilly | 80.3x | 29.5% | US$671.9b |
JNJ Johnson & Johnson | 25.1x | 10.3% | US$370.8b |
MRK Merck | 20.1x | 15.7% | US$243.6b |
AZN AstraZeneca | 29.8x | 18.0% | UK£154.7b |
NNO2 Novo Nordisk | 33x | 14.4% | €3.2t |
Price-To-Earnings vs Peers: NNO2 is good value based on its Price-To-Earnings Ratio (33x) compared to the peer average (38.8x).
Price to Earnings Ratio vs Industry
How does NNO2's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: NNO2 is expensive based on its Price-To-Earnings Ratio (33x) compared to the European Pharmaceuticals industry average (20.7x).
Price to Earnings Ratio vs Fair Ratio
What is NNO2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 33.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NNO2's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €94.60 | €125.75 +32.9% | 20.3% | €154.17 | €75.07 | n/a | 24 |
| Nov ’25 | €103.38 | €126.61 +22.5% | 20.4% | €154.14 | €75.06 | n/a | 24 |
| Oct ’25 | €106.36 | €127.43 +19.8% | 20.3% | €154.25 | €75.11 | n/a | 25 |
| Sep ’25 | €125.50 | €127.40 +1.5% | 20.1% | €160.79 | €75.03 | n/a | 26 |
| Aug ’25 | €123.22 | €129.40 +5.0% | 18.7% | €160.81 | €75.04 | n/a | 26 |
| Jul ’25 | €135.84 | €127.68 -6.0% | 18.3% | €160.91 | €75.09 | n/a | 26 |
| Jun ’25 | €122.00 | €122.99 +0.8% | 18.5% | €150.17 | €71.06 | n/a | 26 |
| May ’25 | €117.50 | €121.18 +3.1% | 19.4% | €150.10 | €71.03 | n/a | 25 |
| Apr ’25 | €121.00 | €119.91 -0.9% | 19.6% | €150.18 | €71.07 | n/a | 25 |
| Mar ’25 | €114.34 | €110.04 -3.8% | 16.8% | €131.50 | €71.12 | n/a | 24 |
| Feb ’25 | €105.60 | €103.43 -2.1% | 18.5% | €131.48 | €60.38 | n/a | 23 |
| Jan ’25 | €93.70 | €96.70 +3.2% | 20.4% | €117.40 | €48.30 | n/a | 23 |
| Dec ’24 | €93.38 | €95.45 +2.2% | 20.2% | €117.41 | €48.31 | n/a | 23 |
| Nov ’24 | €92.20 | €91.64 -0.6% | 21.1% | €110.61 | €48.27 | €103.38 | 22 |
| Oct ’24 | €86.76 | €86.99 +0.3% | 19.7% | €108.61 | €48.27 | €106.36 | 22 |
| Sep ’24 | €87.27 | €82.92 -5.0% | 18.1% | €103.93 | €48.28 | €125.50 | 22 |
| Aug ’24 | €71.54 | €78.28 +9.4% | 15.8% | €97.32 | €48.33 | €123.22 | 23 |
| Jul ’24 | €73.14 | €77.73 +6.3% | 16.2% | €97.32 | €48.32 | €135.84 | 22 |
| Jun ’24 | €73.25 | €77.15 +5.3% | 16.8% | €97.36 | €48.35 | €122.00 | 22 |
| May ’24 | €76.11 | €75.03 -1.4% | 19.5% | €97.30 | €45.63 | €117.50 | 22 |
| Apr ’24 | €73.07 | €68.52 -6.2% | 18.6% | €83.19 | €45.62 | €121.00 | 22 |
| Mar ’24 | €66.83 | €65.82 -1.5% | 17.0% | €82.00 | €45.71 | €114.34 | 23 |
| Feb ’24 | €63.18 | €63.91 +1.2% | 18.3% | €80.66 | €36.30 | €105.60 | 23 |
| Jan ’24 | €63.42 | €60.43 -4.7% | 15.4% | €72.92 | €36.29 | €93.70 | 23 |
| Dec ’23 | €60.20 | €58.65 -2.6% | 15.9% | €72.93 | €36.30 | €93.38 | 24 |
| Nov ’23 | €53.82 | €57.19 +6.3% | 15.6% | €71.88 | €36.28 | €92.20 | 25 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
ALM
€8.44
7D
1.6%
1Y
-2.4%
Teva Pharmaceutical Industries
US$18.6b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$15.65
7D
-4.0%
1Y
87.2%
H. Lundbeck
DKK 42.7b
A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
LUNB
DKK 6.00
7D
2.4%
1Y
33.8%